Germany - medicaments

Description

GWQ ServicePlus AG intends to conclude non-exclusive discount agreements in accordance with § 130a Para. 8 SGB Vzu the above-mentioned active substance with contract commencement on 1 April 2019. The GWQ assumes that this procedure does not fall within the scope of the antitrust procurement law due to the lack of a selection decision and thus the non-discriminatory possibility of access for all pharmaceutical companies. The contract documents, the participating health insurance funds and their turnover as well as the dates for reporting the contract can be viewed and downloaded on the GWQServicePlus AG award portal at http://vergabeportal.gwq-serviceplus.de . Upon receipt of the signed contracts/declaration and evidence by 10.3.2019, an initial notification by 1.4.2019 may be made.The following documents must be submitted:- signed contract in duplicate,- proof of drug approval by means of an extract from the public part of the AMIS database,- signed self-declaration (Annex 3),- PZN list (Annex 4). GWQ ServicePlus AG intends to conclude non-exclusive discount agreements in accordance with § 130a Para. 8 SGB Vzu the above-mentioned active substance with contract commencement on 1 April 2019. The GWQ assumes that this procedure does not fall within the scope of the antitrust procurement law due to the lack of a selection decision and thus the non-discriminatory possibility of access for all pharmaceutical companies. The contract documents, the participating health insurance funds and their turnover as well as the dates for reporting the contract can be viewed and downloaded on the GWQServicePlus AG award portal at http://vergabeportal.gwq-serviceplus.de . Upon receipt of the signed contracts/declaration and evidence by 10.3.2019, an initial notification by 1.4.2019 may be made.The following documents must be submitted:- signed contract in duplicate,- proof of drug approval by means of an extract from the public part of the AMIS database,- signed self-declaration (Annex 3),- PZN list (Annex 4).

Opportunity closing date

10 November 2019

Value of contract

to be confirmed